Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasia

Journal of Urology

Volumn 155, Issue 4, 1996, Pages 1317-1323

  Witjes, Wim P J ^a   Rosier, Peter F W M ^a   De Wildt, Michel J A M ^a   Van Iersel, Matheus P ^a   Debruyne, Frans M J ^a   De La Rosette, Jean J M C H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

adrenergic alpha receptor blockaders; prostate; prostatic hyperplasia; urodynamics

Indexed keywords

TERAZOSIN;

ADULT; AGED; ARTICLE; BLADDER NECK STENOSIS; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SCREENING; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; URINE FLOW RATE; URODYNAMICS;

EID: 0029878038     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)66255-4     Document Type: Article

References (20)

1. Garraway, W. M., Collins, G. N. and Lee, R. J.: High prevalence of benign prostatic hypertrophy in the community. Lancet, 338: 469, 1991.
2. Bruskewitz, R. C., Larsen, E. H., Madsen, P. O. and Dørflinger, T.: 3-Year followup of urinary symptoms after transurethral resection of the prostate. J. Urol., 136: 613, 1986.
3. Schäfer, W., Nopponey, R., Rubben, G. and Lutzeyer, W.: The value of free flow rate and pressure-flow studies in the routine investigation of BPH patients. Neurourol. Urodynam., 7: 219, abstract 42, 1988.
4. Roos, N. P., Wennberg, J. E., Malenka, D. J., Fischer, E. S., McPherson, K., Folmer-Anderson, T., Cohen, M. M. and Ramsey, E.: Mortality and re-operation after open and transurethral resection of the prostate for benign prostatic hyperplasia. New Engl. J. Med., 320: 1120, 1989.
5. Caine, M., Pfau, A. and Perlberg, S.: The use of alpha-adrenergic blockers in benign prostatic obstruction. Brit. J. Urol., 48:255, 1976.
6. Kirby, R. S., Copinger, S. W. C., Corcoran, M. O., Chapple, C. R., Flannagan, M. and Milroy, E. J. G.: Prazosin in the treatment of prostatic obstruction: a placebo-controlled study. Brit. J. Urol., 60: 136, 1987.
7. 1 blocker for the treatment of symptomatic benign prostatic hyperplasia. J. Urol., 144: 1393, 1990.
8. Chapple, C. R., Carter, P., Christmas, T. J., Kirby, R. S., Bryan, J., Milroy, E. J. G. and Abrams, P.: A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Brit. J. Urol., 74: 50, 1994.
9. Debruyne, F. M. J., Denis, L., Arocena, F., Kirk, D., Kirby, R. and the ITT group: Efficacy of terazosin in benign prostatic hyperplasia from a randomized withdrawal International Terazosin Trial (ITT). J. Urol., part 2, 153: 273A, abstract 177, 1995.
10. Ekman, P., Witjes, W. P. J. and the International Terazosin Trial Group: Nocturia results from the International Terazosin Trial. A double-blind, placebo-controlled randomized withdrawal study of the symptomatic treatment of BPH. In: 23rd Congress of the Societé Internationale d'Urologie. Sydney, Australia, abstract 98, September 18-22, 1994.
11. Schäfer, W.: The contribution of the bladder outlet to the relation between pressure and flowrate during voiding. In: Benign Prostatic Hypertrophy. Edited by F. Hinman, Jr. and S. Boyarsky. New York: Springer-Verlag, pp. 470-496, 1983.
12. Griffiths, D., van Mastrigt, R. and Bosch, R.: Quantification of urethral resistance and bladder function during voiding, with special reference to the effects of prostate size reduction on urethral obstruction due to benign prostatic hyperplasia. Neurourol. Urodynam., 8: 17, 1989.
13. Schäfer, W.: Principles and clinical application of advanced urodynamic analysis of voiding function. Urol. Clin. N. Amer., 17: 553, 1990.
14. Abrams, P., Blaivas, J., Nordling, J., Griffiths, D. J., Kondo, A., Koyanagi, T., Neal, D., Schäfer, W. and Yalla, S.: The objective evaluation of bladder outflow obstruction. In: The 2nd International Consultation on Benign Prostatic Hyperplasia (BPH). Edited by A. T. K. Cockett, S. Khoury, Y. Aso, C. Chatelain, L. Denis, K. Griffiths and G. Murphy. Jersey: Scientific Communication International Ltd., pp. 153-209, 1993.
15. Golomb, J., Lindner, A., Siegel, Y. and Korczak, D.: Variability and circadian changes in home uroflowmetry in patients with benign prostatic hyperplasia compared to normal controls. J. Urol., 147: 1044, 1992.
16. Drach, G. W., Layton, T. and Bottaccini, M. R.: A method of adjustment of male peak urinary flow rate for varying age and volume voided. J. Urol., 128: 960, 1982.
17. Aso, Y., Boccon-Gibbod, L., Brendler, B., Calais da Silva, F., Cockett, A. T. K., Fowler, J. E., Homma, Y., Moriyama, N., Okajima, E. and Richard, F.: Clinical research criteria. In: The 2nd International Consultation on Benign Prostatic Hyperplasia (BPH). Edited by A. T. K. Cockett, S. Khoury, Y. Aso, C. Chatelain, L. Denis, K. Griffiths and G. Murphy. Jersey: Scientific Communication International Ltd., pp. 343-358, 1993.
18. Tammela, T. L. J. and Kontturi, M. J.: Urodynamic effects of finasteride in the treatment of bladder outlet obstruction due to benign prostatic hyperplasia. J. Urol., 149: 342, 1993.
19. 1 adrenergic receptor subtypes in human prostate. J. Urol., 150: 546, 1993.
20. Schalken, J. A., van Stratum, P., Smit, F., van Bokhoven, A., de la Rosette, J., Korstanje, C. and Debruyne, F. M. J.: Differential expression of α1-adrenergic receptor subtypes in BPH determined by reverse transcriptase polymerase chain reaction. In: 23rd Congress of the Societé Internationale d'Urologie. Sydney, Australia, abstract 648, September 18-22, 1994.